Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06816355 · ClinicalTrials.gov registry record
Exogenous Sex Hormones and PONV
A clinical trial, sponsored by Riverside University Health System Medical Center.
- Completed
- Registry status
- 7,348
- Enrollment target
NCT06816355: Completed study, sponsored by Riverside University Health System Medical Center.
NCT06816355 is a clinical trial that has completed, run by Riverside University Health System Medical Center. The registered enrollment target is 7,348 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06816355 has completed, sponsored by Riverside University Health System Medical Center.
- COMPLETED
- Registry status
- 7,348 participants
- Enrollment target
Study Summary
This study aims to investigate the rates of postoperative nausea and vomiting in transgender patients on hormone therapy compared to cisgender patients undergoing the same procedures (hysterectomy, orchiectomy, augmentation mammoplasty).
Primary Outcome
The primary outcome will be the administration of a rescue antiemetic within 24 hours of surgery. Rescue antiemetics will include droperidol, promethazine, dimenhydrinate, metoclopramide, and prochlorperazine based on rescue antiemetics from the Fourth Consensus PONV Guidelines.
Interventions
- PROCEDURE Hysterectomy
- PROCEDURE Orchiectomy
- PROCEDURE Augmentation mammoplasty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,348 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2025-02-04 |
What the finished NCT06816355 record still lists
NCT06816355 is an observational study that tracks outcomes without assigning an intervention. Its 7,348 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Hysterectomy is the first listed.
NCT06816355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06816355 about?
NCT06816355 is a clinical study titled "Exogenous Sex Hormones and PONV". This study aims to investigate the rates of postoperative nausea and vomiting in transgender patients on hormone therapy compared to cisgender patients undergoing the same procedures (hysterectomy, orchiectomy, augmentation mammoplasty).
What is the current status of trial NCT06816355?
This trial is currently completed. The enrollment target is 7,348 participants. The study started on 2025-02-04. Estimated completion is 2025-02-04.
What interventions are being tested in trial NCT06816355?
The interventions under investigation include: Hysterectomy (PROCEDURE), Orchiectomy (PROCEDURE), Augmentation mammoplasty (PROCEDURE).
Who is sponsoring clinical trial NCT06816355?
This trial is sponsored by Riverside University Health System Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT05049837 · 7,200 participants
PROSPECT - Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification
- NCT06714929 · 7,200 participants · NA
Advancing Water Security: A Community Participatory School-Based Hydration Intervention
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI